Skip to main content

Articles

Leukemia, Oncology

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL

Phoebe Starr

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies

Charles Bankhead

Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma

Wayne Kuznar

Practice Management

Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer

Chase Doyle

FDA Approvals, In the News

FDA Approves Pembrolizumab for Treatment of Advanced Melanoma

Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective

Kenneth LaPensee, PhD; Rohit Mistry, MPharm, MBA, MSc; Thomas Lodise, PharmD, PhD

Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections

Kenneth LaPensee, PhD; Rohit Mistry, MPharm, MBA, MSc; Thomas Lodise, PharmD, PhD

Original Research, Cardiometabolic Health

Implementation of a Pharmacist-Led Diabetes Management Protocol

Lana T. Al-Omar, PharmD, BCPS; Sarah L. Anderson, PharmD, FCCP, BCPS, BCACP; Amber D. Cizmic, PharmD, BCACP; Tara B. Vlasimsky, PharmD, BCPS, BCACP

Stakeholder Perspective

Collaborative Efforts Help the Avoidance of Diabetes Mismanagement

Jack E. Fincham, PhD, RPh

Case Study, Practice Management

The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab

Diana Brixner, RPh, PhD; Gary Oderda, PharmD, MPH; Joseph Biskupiak, PhD, MBA; Douglas S. Burgoyne, PharmD, FAMCP; Steven G. Avey, RPh, MS, FAMCP; Steven R. Feldman, MD, PhD

Practice Management

US Healthcare Trends and Contradictions in 2019

F. Randy Vogenberg, PhD

Page 60 of 245
Results 591 - 600 of 2441